FDA Gives Thumbs-Up to PureCircle Products

PureCircle has announced that the US Food and Drug Administration (FDA) has issued a No Objection letter for the use of PureCircle’s SG95 product as a Food and Beverage ingredient in the USA. This will enable PureCircle to offer a wider and more flexible array of stevia solutions to manufacturers in the US market.

PureCircle is working with Imperial Sugar Company through a joint venture – Natural Sweet Ventures, L.L.C. – to develop stevia – cane sugar products in the U.S.

PureCircle’s high purity SG95 product is a further example of the company’s leadership in innovation. Along with seven previously approved steviol glycosides, SG95 includes two new steviol glycosides, Rebaudioside D and Rebaudioside F, both of which are receiving GRAS No Objection for the first time.

The new high purity sweetener delivers great taste and consistency, as well as pricing well below sugar. The product is suited for applications formulated with both sugar and SG95 to achieve a low cost solution to partial sugar and calorie reduction. Together with PureCircle’s successful high purity Reb A 97, SG95 will provide customers with an expanded range of options to improve products across their portfolios.

With GRAS affirmation, PureCircle is prepared for immediate commercialization of SG95.
Magomet Malsagov, CEO and Managing Director of PureCircle, stated “The launch of SG95 is a very exciting development for PureCircle in the United States with considerable future potential in global markets. Expanded use of sweet glycosides from the stevia plant provides both formulation and economic benefits to our customers.

“PureCircle’s Reb A 97 continues to play a major role in the company’s portfolio, particularly as investments yield continued efficiencies that will be shared with customers. Now, SG95 will provide an additional compelling product today in many applications.”